A Research Guide for
COPD

Your blood eosinophil count (BEC) has become one of the most important numbers in COPD management. Eosinophils are a type of white blood cell involved in certain types of inflammation. In COPD:

• ≥300 cells/μL — strongly favors treatment with inhaled corticosteroids (ICS). These patients are also candidates for biologic therapy (dupilumab or mepolizumab) if they remain uncontrolled on triple therapy.
• 100–300 cells/μL — ICS may benefit, especially if there is a history of frequent exacerbations. Decisions are made on a case-by-case basis.
• <100 cells/μL — ICS is less likely to help and may increase the risk of pneumonia without meaningful benefit. Non-ICS strategies are preferred.

Your eosinophil count should be checked as part of your routine COPD workup. Ask your doctor what your level is — it directly shapes your treatment plan.

Alpha-1 antitrypsin deficiency (AATD) is a genetic condition in which the liver does not produce enough of a protein that protects the lungs. Without this protection, the lungs are vulnerable to damage, especially from smoking or environmental exposures. AATD causes about 1–3% of COPD cases and can cause emphysema at an unusually young age (before 45–50).

The GOLD guidelines recommend that every person diagnosed with COPD should be tested for AATD at least once. The test is a simple blood draw measuring the alpha-1 antitrypsin protein level. If the level is low, genetic testing (phenotyping or genotyping) determines the specific variant.

If you have AATD, a specific treatment — alpha-1 antitrypsin augmentation therapy (weekly IV infusions of the missing protein) — is available and has been shown to slow lung tissue loss. Identifying AATD also has implications for your family members, who should be tested.

A chest CT scan is not required for COPD diagnosis but provides valuable information:

• Emphysema pattern and distribution — CT can show where and how extensively the air sacs are destroyed. Upper-lobe-predominant emphysema is important for evaluating lung volume reduction procedures.
• Bronchiectasis — abnormal widening of the airways, which co-occurs with COPD in some patients and affects treatment choices.
• Lung cancer screening — people with COPD are at increased risk for lung cancer. Low-dose CT screening is recommended for current or former heavy smokers.
• Pulmonary hypertension — CT can suggest increased pressure in the lung arteries, which develops in advanced COPD.

The DLCO (diffusing capacity of the lungs for carbon monoxide) measures how efficiently oxygen crosses from the air sacs into your bloodstream. You breathe in a tiny, harmless amount of carbon monoxide, hold your breath for about 10 seconds, and blow out. The test takes about 15 minutes.

In emphysema, the destruction of air sac walls reduces the surface area for gas exchange, and DLCO is reduced. A low DLCO helps confirm emphysema and may influence decisions about oxygen therapy, surgical eligibility, and exercise capacity. DLCO is often normal or near-normal in chronic bronchitis without significant emphysema.

Several other conditions can cause similar symptoms, and your doctor may test for these:

• Asthma — airflow obstruction in asthma is typically reversible, while in COPD it is persistent. Some patients have "asthma-COPD overlap." Distinguishing asthma from COPD affects treatment choices.
• Heart failure — can cause breathlessness and fluid in the lungs. Heart failure and COPD commonly coexist.
• Bronchiectasis — abnormal widening of the airways with chronic infection and sputum production.
• Interstitial lung disease — scarring of the lung tissue.
• Lung cancer — can cause cough, breathlessness, and weight loss. Lung cancer screening is important for COPD patients.

• What did my spirometry show? What is my FEV1 and my GOLD grade?
• What is my ABE group, and what does that mean for my treatment?
• What is my blood eosinophil count?
• Have I been tested for alpha-1 antitrypsin deficiency?
• Did my CT scan show emphysema, bronchiectasis, or anything else important?
• What is my DLCO, and what does it tell us about my lungs?
• Should I be screened for lung cancer?
• How often should my lung function be retested?
• Am I at risk for pulmonary hypertension?

Two landmark trials established single-inhaler triple therapy as superior to dual therapy for exacerbation-prone COPD patients:

• IMPACT trial (Trelegy) — 10,355 patients across 37 countries. Triple therapy reduced moderate-to-severe exacerbations by 25% compared to LAMA/LABA and by 15% compared to ICS/LABA. An expanded analysis also showed a 42% reduction in all-cause mortality versus LAMA/LABA.
• ETHOS trial (Breztri) — 8,588 patients. Triple therapy reduced exacerbations by 24% compared to LAMA/LABA and by 13% compared to ICS/LABA. A 46% reduction in all-cause mortality was observed versus LAMA/LABA.

Important caveat about mortality data: neither trial was designed with mortality as its primary endpoint, and the FDA advisory committee rejected the mortality claim for the Trelegy label. A significant concern is the "ICS withdrawal effect" — 70–80% of patients in the LAMA/LABA arms had ICS withdrawn at enrollment, and the excess deaths were concentrated in the first 90 days (when ICS withdrawal effects are strongest). During the remaining nine months, no mortality difference was observed. Triple therapy clearly reduces exacerbations, but whether it extends life remains an open question.

COPD inhalers come in several device types. The "best" inhaler is the one you can use correctly and consistently:

• Metered-dose inhalers (MDIs) — small, portable canisters. Require coordination between pressing the canister and breathing in. Using a spacer (a chamber that attaches to the MDI) improves delivery and reduces the need for perfect timing.
• Dry powder inhalers (DPIs) — breath-activated (no coordination needed). Require a strong enough inhalation to pull the powder into the lungs. May be difficult for patients with very severe airflow limitation.
• Soft mist inhalers (Respimat) — produce a slow-moving mist that is easier to inhale. Good option for patients who struggle with MDIs or DPIs.
• Nebulizers — convert liquid medication into a fine mist inhaled through a mouthpiece or mask over 5–15 minutes. Do not require coordination or strong inhalation. Used for ensifentrine and for patients who cannot use handheld devices effectively.

When switching from one device to another, always receive hands-on training from a healthcare provider. Consistent use of the correct device is as important as the medication itself.

The GOLD guidelines provide a structured approach to escalating therapy based on symptoms, exacerbation history, and eosinophil count:

1. Group A — Start with any single bronchodilator (LAMA or LABA).
2. Group B — LAMA + LABA preferred (dual bronchodilation).
3. Group E — LAMA + LABA. If eosinophils ≥300 cells/μL, consider ICS + LAMA + LABA (triple therapy).
4. If still uncontrolled on triple therapy — Add-on options: roflumilast (chronic bronchitis phenotype), azithromycin prophylaxis, and for patients with eosinophils ≥300 cells/μL, biologic therapy (dupilumab or mepolizumab).

The GOLD 2026 guidelines also introduce "disease activity" as a formal therapeutic target. The goal is not just symptom relief — it is zero exacerbations, stable symptoms, and no accelerated lung function decline.

• Which inhaler or combination of inhalers is right for me based on my symptoms, eosinophil count, and exacerbation history?
• Can you (or a respiratory therapist) watch me use my inhaler and show me if I am doing it correctly?
• Am I a candidate for single-inhaler triple therapy (Trelegy or Breztri)?
• Should I consider ensifentrine (Ohtuvayre) as an add-on to my current therapy?
• Is roflumilast or azithromycin appropriate for me?
• What should I do when my symptoms suddenly worsen? Do I have an action plan?
• Am I using any inhalers or medications that I could safely stop?
• Should I be considered for a biologic therapy based on my eosinophil count?
• Are there clinical trials for new COPD medications that I could join?

Both biologics target eosinophilic inflammation in COPD but through different pathways:

• Dupilumab (Dupixent): blocks IL-4 and IL-13 (broad type 2 inflammation). Eosinophil threshold ≥300 cells/μL. Dosing: every 2 weeks. Exacerbation reduction: 30–34% in trials. Approved for COPD since September 2024.
• Mepolizumab (Nucala): blocks IL-5 (targets eosinophil production specifically). Evaluated at a lower eosinophil threshold (≥150 cells/μL). Dosing: once monthly (less frequent). Exacerbation reduction: 21% in MATINEE. Approved for COPD since May 2025.

There are no head-to-head trials comparing the two biologics directly. Your pulmonologist will consider your eosinophil level, dosing preference (every 2 weeks vs. monthly), other conditions you may have (dupilumab is also approved for atopic dermatitis, asthma, and nasal polyps), and insurance coverage. Both represent a genuine step forward for patients with eosinophilic COPD who remain uncontrolled on inhaled therapy.

Lung volume reduction surgery involves surgically removing the most damaged portions of the emphysematous lung to allow the remaining healthier lung tissue to function better. The NETT (National Emphysema Treatment Trial) established that LVRS benefits patients with upper-lobe-predominant emphysema and low exercise capacity after pulmonary rehabilitation.

LVRS is a major surgical procedure and is only appropriate for carefully selected patients. It requires thorough evaluation including pulmonary function testing, CT imaging, cardiac assessment, and completion of a pulmonary rehabilitation program. The decision to pursue LVRS versus endobronchial valves depends on the pattern and distribution of emphysema, fissure integrity, and surgical risk.

Lung transplantation is an option for patients with very severe COPD (GOLD 4) who continue to deteriorate despite maximal medical therapy, pulmonary rehabilitation, and other interventions. COPD is the most common indication for lung transplantation worldwide.

Transplant evaluation is complex and considers age, other health conditions, nutritional status, psychosocial support, and the ability to adhere to a lifelong immunosuppressive medication regimen. Referral to a transplant center should be considered when:

• FEV1 falls below 20–25% predicted despite optimal therapy
• Frequent severe exacerbations requiring hospitalization or ICU admission
• Development of pulmonary hypertension
• Rapidly declining lung function despite maximal treatment

In Utah, the University of Utah Health Lung Transplant Program serves as the regional transplant center.

For patients with alpha-1 antitrypsin deficiency (AATD), augmentation therapy involves weekly intravenous infusions of purified alpha-1 antitrypsin protein derived from human plasma. This replaces the protective protein the body cannot make enough of.

• Available products: Prolastin-C, Zemaira, Glassia, Aralast NP.
• Evidence: the RAPID trial and its open-label extension demonstrated that augmentation therapy slows the loss of lung tissue as measured by CT densitometry.
• Who qualifies: patients with documented severe AATD (PiZZ or other severe-deficient phenotypes) and evidence of emphysema.
• Limitations: augmentation therapy is a lifelong weekly infusion and is expensive. It slows disease progression but does not reverse existing damage.

Investigational approaches: fazirsiran, an RNA interference (RNAi) therapy, is in Phase 3 trials targeting the liver manifestations of AATD. Gene therapy (AAV-based) to deliver a functional AAT gene is in early-phase (Phase 1) clinical trials. These represent potential future alternatives to lifelong infusions.

The COPD pipeline is more active than it has been in decades. While these are not yet approved, they represent the next wave of potential treatments:

• Itepekimab (anti-IL-33, Sanofi/Regeneron) — targets IL-33, an upstream "alarm signal" that triggers broad inflammation. The AERIFY-1 Phase 3 trial met its primary endpoint with a 27% reduction in exacerbations in former smokers, but the AERIFY-2 trial missed its primary endpoint. Results are mixed, and the company is assessing data with regulators.
• Tezepelumab (anti-TSLP, AstraZeneca) — targets thymic stromal lymphopoietin (TSLP), another upstream inflammatory signal. The Phase 2a COURSE trial did not meet its primary endpoint overall, but a subgroup with eosinophils ≥150 cells/μL showed a 37% exacerbation reduction. Phase 3 trials (EMBARK) are now recruiting, with results expected around 2029.
• Tozorakimab (anti-IL-33, AstraZeneca) — an antibody that blocks IL-33, an upstream "alarmin" that drives airway inflammation. In March 2026, AstraZeneca announced that both of its large Phase 3 trials (OBERON and TITANIA) met their main goal, reducing flare-ups in both former and current smokers across all eosinophil levels. It is not yet FDA-approved — the company is expected to file for approval — but it is one of the most promising COPD drugs in late-stage development.
• HRS-9821 (PDE3/4 inhibitor, GSK/Hengrui) — a potential competitor to ensifentrine, in clinical development as part of a broad GSK respiratory partnership.
• Ensifentrine combinations — a fixed-dose combination of ensifentrine with glycopyrrolate (LAMA) is in development, which could combine a novel bronchodilator/anti-inflammatory mechanism with a standard LAMA in one product.
• siRNA (RNA interference) therapy — GSK acquired global rights to an investigational siRNA therapy targeting lung inflammation, representing a novel approach to COPD. Early-stage development.

Clinical trials are not a last resort — they offer access to cutting-edge approaches. Ask your pulmonologist about trial eligibility at every visit.

With more advanced options now available, your pulmonologist considers several factors:

• Eosinophil count — biologics are for patients with eosinophilic inflammation (≥150 or ≥300 cells/μL depending on the biologic). If your eosinophils are low, biologics are unlikely to help and other approaches (roflumilast, azithromycin, bronchoscopic interventions) are considered.
• COPD phenotype — emphysema-predominant with hyperinflation? Endobronchial valves or LVRS may be appropriate. Chronic bronchitis-predominant with frequent exacerbations? Roflumilast, azithromycin, or biologics (if eosinophilic).
• Exacerbation frequency — patients with frequent exacerbations despite triple therapy are the priority for escalation to biologics or add-on oral therapies.
• Alpha-1 antitrypsin status — AATD requires specific augmentation therapy.
• Disease severity — very severe COPD with continued decline may warrant transplant evaluation.
• Comorbidities — heart disease, osteoporosis, anxiety, depression, and other conditions must be managed alongside COPD. Some treatments (long-term oral steroids, azithromycin) carry risks that must be weighed against benefits.
• Cost and insurance — biologics cost approximately $55,000/year. Ensifentrine costs about $2,950/month. Prior authorization and patient assistance programs are important to explore early.

• Am I a candidate for a biologic therapy (dupilumab or mepolizumab)? What is my eosinophil count?
• What is the difference between dupilumab and mepolizumab, and which might be better for my situation?
• Could ensifentrine (Ohtuvayre) be added to my current treatment?
• Am I a candidate for endobronchial valve therapy or lung volume reduction surgery?
• Should I be evaluated for lung transplantation?
• Have I been tested for alpha-1 antitrypsin deficiency, and if positive, should I start augmentation therapy?
• Are there clinical trials I should consider?
• What financial assistance is available for these advanced treatments?
• What should I expect in terms of how quickly the biologic will work?
• How will we measure whether the advanced treatment is helping?

Supplemental oxygen is prescribed for COPD patients with significantly low blood oxygen levels (severe resting hypoxemia). It is one of the few COPD treatments proven to improve survival — but only in the right patients:

• Proven benefit: patients with severe resting hypoxemia (PaO2 ≤55 mmHg or SpO2 ≤88%) who use oxygen for ≥15 hours per day have improved survival. This has been established since the landmark NOTT and MRC trials in the 1980s.
• No proven benefit for moderate hypoxemia: the LOTT trial (published 2016, over 700 patients) found that supplemental oxygen did not improve survival, hospitalization rates, or quality of life in patients with only moderate resting or exercise-induced low oxygen levels (SpO2 89–93%).
• Ambulatory oxygen: oxygen during exercise may help some patients exercise longer and with less breathlessness, even if resting levels are adequate. This is evaluated on a case-by-case basis.

If you are on supplemental oxygen, use it as prescribed. If your oxygen levels are only moderately low, discuss the LOTT trial findings with your doctor — oxygen may not be the best intervention for you.

A COPD action plan is a written document, developed with your care team, that tells you exactly what to do when your symptoms change. It typically uses a traffic-light system:

• Green zone (doing well): your usual symptoms and medication routine. Continue your maintenance therapy and healthy habits.
• Yellow zone (getting worse): increased breathlessness, more cough or sputum, sputum changing color, more frequent rescue inhaler use. The plan tells you to increase specific medications (e.g., start a short course of prednisone, start an antibiotic if sputum has changed color), and when to call your doctor.
• Red zone (emergency): severe breathlessness at rest, confusion, blue lips or fingertips, chest pain. Call emergency services immediately.

Having a written action plan reduces emergency department visits and hospitalizations. Ask your doctor to create one with you, and keep it where you (and your caregiver) can find it easily.

Nutrition is an often-overlooked aspect of COPD management. Both overweight and underweight create problems:

• Underweight and muscle wasting: advanced COPD can cause significant weight loss and muscle wasting (cachexia). This is a serious problem because weakened respiratory muscles make breathing harder. If you are losing weight unintentionally, tell your doctor. A dietitian can help optimize caloric intake and protein for muscle maintenance.
• Overweight and obesity: excess weight increases the work of breathing and can worsen breathlessness. Weight management through balanced nutrition and activity (as tolerated) is important.
• Eating tips for breathlessness: eat smaller, more frequent meals rather than large ones (a full stomach pushes up on the diaphragm). Rest before eating. Choose nutrient-dense foods. Avoid gas-producing foods that cause bloating. Eat slowly and breathe between bites.
• Hydration: adequate fluid intake helps keep mucus thin and easier to clear. Unless you are on a fluid restriction for another condition, aim for adequate hydration throughout the day.

It is natural to avoid activity when you feel breathless, but inactivity creates a vicious cycle: less activity leads to weaker muscles, which leads to more breathlessness, which leads to even less activity. Breaking this cycle is one of the most important things you can do:

• Start slowly and build gradually. Even 5–10 minutes of walking is a meaningful start if that is all you can manage.
• Use pursed-lip breathing during exertion: breathe in through your nose for 2 counts, then out slowly through pursed lips for 4 counts. This helps prevent air trapping and reduces breathlessness.
• Use your rescue inhaler before exercise if your doctor recommends it — taking albuterol 15–30 minutes before activity can help you exercise more comfortably.
• Strength training matters: maintaining arm and leg strength helps with daily activities. Even light resistance exercises or chair-based workouts make a difference.
• Continue after pulmonary rehab: the benefits of pulmonary rehabilitation fade if exercise stops. Establish a home exercise routine or join a maintenance program.

Anxiety and depression are extremely common in COPD — affecting up to 40% of patients — and are often undertreated. The breathlessness of COPD can trigger panic and anxiety, which in turn worsens the sensation of breathlessness, creating a difficult cycle. Depression is fueled by activity limitation, social isolation, and the burden of chronic disease.

These conditions are treatable and should be treated. Untreated anxiety and depression worsen COPD outcomes, reduce medication adherence, and increase exacerbation risk. Tell your care team if you are feeling anxious, depressed, or hopeless. Treatment options include:

• Cognitive behavioral therapy (CBT) — highly effective for COPD-related anxiety and breathlessness management
• Medications for anxiety and depression (SSRIs are generally safe in COPD)
• Pulmonary rehabilitation (addresses both physical and psychological wellbeing)
• Support groups and peer connections
• Mindfulness and relaxation techniques

• Air travel: cabin pressure is equivalent to about 6,000–8,000 feet altitude, which reduces oxygen levels. If your resting SpO2 is borderline (≤92%), ask your doctor about a "hypoxia altitude simulation test" (HAST) to see if you need supplemental oxygen for flying. Airlines require advance notice for in-flight oxygen.
• Carry medications in your hand luggage — never pack inhalers or medications in checked baggage.
• Bring extra medication — enough for the entire trip plus several extra days in case of delays.
• Carry your COPD action plan and medication list.
• Travel insurance: ensure your policy covers COPD-related events and hospital admissions.
• Altitude: high-altitude destinations may worsen breathlessness. Discuss plans with your doctor.

Advance care planning is an important conversation for everyone with COPD, particularly those with severe disease or frequent hospitalizations. It is not about giving up — it is about ensuring your wishes are known and respected:

• Complete an advance directive (living will) and designate a healthcare proxy (someone who can make medical decisions if you cannot).
• Discuss with your doctor: at what point would you want to focus on comfort rather than aggressive treatments? What are your goals and values?
• Palliative care is not the same as end-of-life care. Palliative care focuses on symptom management and quality of life at any stage of disease. Ask about palliative care services if your symptoms are difficult to control, even if you are pursuing all active treatments.
• Share your advance directive with your doctor, your caregiver, and your designated proxy.
• Review and update these documents periodically, especially after major changes in your health.

There is no single "best" way to quit smoking — the best method is the one that works for you. Most people need a combination of medication and behavioral support:

• Nicotine replacement therapy (NRT) — patches, gum, lozenges, nasal spray, and inhalers. Available over the counter (patches, gum, lozenges) and by prescription (nasal spray, inhaler). NRT roughly doubles quit rates compared to willpower alone. Combining a long-acting form (patch) with a short-acting form (gum or lozenge for cravings) is more effective than either alone.
• Varenicline (Chantix) — a prescription medication that reduces nicotine cravings and makes smoking less satisfying. It is the most effective single medication for smoking cessation. The FDA removed its black-box warning for neuropsychiatric side effects after large safety trials showed these concerns were overstated.
• Bupropion (Wellbutrin/Zyban) — an antidepressant that also reduces nicotine cravings. Can be combined with NRT.
• Behavioral counseling — individual, group, or telephone counseling improves quit rates, especially when combined with medication. The Utah Tobacco Quit Line (1-800-QUIT-NOW) provides free counseling.
• E-cigarettes/vaping — the role of e-cigarettes in smoking cessation remains controversial. Some evidence suggests they can help some smokers quit, but they are not FDA-approved cessation aids, and long-term safety data are limited. Discuss with your doctor.

Most smokers need multiple quit attempts before succeeding. A "failed" attempt is not a failure — it is practice. Every day without a cigarette benefits your lungs.

COPD rarely occurs alone. Most patients have one or more coexisting conditions that influence symptoms, quality of life, and treatment choices:

• Heart disease — coronary artery disease and heart failure are the most common comorbidities in COPD. The shared risk factor of smoking, plus systemic inflammation, contribute. Breathlessness in COPD can mask heart disease symptoms. Cardiac evaluation is important in all COPD patients.
• Osteoporosis — long-term oral corticosteroid use, inactivity, smoking, and the inflammatory nature of COPD all increase fracture risk. Bone density screening should be considered, especially if you have had prolonged steroid courses.
• Anxiety and depression — extremely common (up to 40% of COPD patients) and often undertreated. See the mental health section above.
• Lung cancer — COPD is an independent risk factor for lung cancer beyond the shared risk of smoking. Low-dose CT screening is recommended for eligible patients.
• Gastroesophageal reflux (GERD) — common in COPD and can worsen respiratory symptoms. Treatment of GERD may reduce exacerbations.
• Diabetes — systemic corticosteroid use during exacerbations can worsen blood sugar control. If you have diabetes, your care team should coordinate glucose management during steroid courses.
• Sleep disorders — obstructive sleep apnea can coexist with COPD ("overlap syndrome"), worsening nighttime oxygen levels. If you snore heavily or feel excessively sleepy during the day, mention this to your doctor.

Managing comorbidities is as important as managing COPD itself. Tell your pulmonologist about all of your health conditions, and make sure each specialist knows about the others.

Specific breathing techniques can help you manage breathlessness during daily activities:

• Pursed-lip breathing — breathe in slowly through your nose for 2 counts. Purse your lips as if whistling or blowing out a candle. Breathe out slowly and gently through your pursed lips for 4 counts. This slows your breathing, keeps airways open longer, and helps release trapped air. Use during exertion and when you feel breathless.
• Diaphragmatic breathing — place one hand on your chest and one on your belly. Breathe in through your nose so your belly pushes out against your hand (your chest should stay relatively still). Breathe out slowly through pursed lips, letting your belly fall. This strengthens the diaphragm and improves breathing efficiency.
• Positioning for breathlessness — leaning forward while seated (elbows on knees or on a table) or standing and leaning on a counter opens the chest and helps the diaphragm work more effectively. This is a useful rescue position when you feel very breathless.
• Pacing activities — break tasks into smaller steps with rest periods in between. Exhale during the exertion part of an activity (e.g., breathe out while lifting, bending, or climbing). This prevents breath-holding, which worsens air trapping.

COPD exacerbations (flare-ups) are acute worsenings of symptoms beyond normal day-to-day variation. They are not just unpleasant episodes — they are disease-defining events with lasting consequences:

• Each severe exacerbation causes a permanent drop in lung function that is often not fully recovered.
• Frequent exacerbations accelerate the decline of FEV1 over time.
• Exacerbations increase the risk of future exacerbations (a "frequent exacerbator" pattern tends to persist).
• Hospital admissions for COPD exacerbations carry a 30-day readmission rate of approximately 20% and a significant mortality risk.
• The period immediately after an exacerbation is the highest-risk time for another one. GOLD 2026 emphasizes structured discharge bundles and timely follow-up.

Prevention is the goal: the entire treatment strategy — bronchodilators, ICS (if eosinophilic), biologics, pulmonary rehabilitation, vaccinations, smoking cessation, and action plans — is designed to minimize exacerbation frequency and severity.

The GOLD 2026 guidelines formally recognize the emerging role of technology in COPD management:

• Smart inhalers — devices with built-in sensors that track when and how you use your inhaler, sending data to an app on your phone. They can remind you to take your medication and detect if your technique is correct. Several are now commercially available.
• Pulse oximeters — inexpensive fingertip devices that measure your blood oxygen saturation (SpO2). Useful for monitoring at home, especially during exacerbations or exercise. Normal SpO2 is typically 94–98%.
• Telehealth — virtual visits with your pulmonology team can reduce the need for in-person visits for routine follow-ups and medication adjustments, especially for patients with mobility limitations.
• Virtual pulmonary rehabilitation — remote programs that deliver exercise guidance and education at home. These are now recognized as valid alternatives to in-person programs, improving access for patients who cannot travel to a rehab center.
• Self-management apps — several apps help COPD patients track symptoms, medications, and exacerbations, and can alert you (and your care team) to worsening trends.

Ask your care team about digital tools that might help you manage your COPD more effectively.

• Support smoking cessation. If your loved one is still smoking, this is the single most impactful area where you can help. Be supportive and non-judgmental. Avoid nagging, which can be counterproductive. Offer to accompany them to cessation counseling or to remove smoking triggers from the home.
• Help with inhaler technique. Proper inhaler use is essential. Learn how each device works so you can help troubleshoot. Watch training videos together.
• Encourage pulmonary rehabilitation and exercise. Help with transportation to rehab sessions. Exercise together when possible — even short walks matter.
• Recognize worsening symptoms early. Watch for increased breathlessness, more coughing, change in sputum color (from white/clear to yellow/green), increased sputum volume, and fatigue. These may signal an exacerbation that needs early treatment.
• Keep the action plan accessible. Know where the COPD action plan is and what steps to follow when symptoms worsen.
• Help manage medications. COPD patients often take multiple inhalers and medications. Help organize a medication schedule, refill prescriptions, and track prior authorizations for expensive therapies.
• Maintain a smoke-free home. Secondhand smoke and indoor air pollution worsen COPD. Ensure the home environment is clean, well-ventilated, and free of fumes, strong chemicals, and dust.

Call 911 or go to the emergency room immediately if:

• Severe breathlessness at rest that does not improve with rescue inhalers
• Confusion or drowsiness (may indicate dangerously high carbon dioxide levels)
• Blue lips, fingertips, or face (cyanosis)
• Chest pain
• Rapid or irregular heartbeat
• Inability to speak more than a few words due to breathlessness

Contact the care team promptly for:

• Fever or signs of respiratory infection
• Increased sputum production or change in sputum color
• Worsening breathlessness over hours or days beyond usual pattern
• Increased need for rescue inhaler
• Swelling in ankles or legs (may indicate right heart strain)

Caring for someone with a chronic progressive lung disease is demanding. The constant worry about breathing, the impact of exacerbations, and the limitations on activities take a toll on caregivers too. Protect yourself:

• Keep your own medical appointments and maintain your own health.
• Accept help from friends, family, and community resources.
• Consider a caregiver support group — the COPD Foundation and American Lung Association offer resources.
• Recognize caregiver burnout: exhaustion, irritability, withdrawal, and physical symptoms. Seek support if you experience these.
• Your wellbeing directly affects the quality of care you can provide. Taking care of yourself is not selfish — it is essential.

• What smoking cessation method do you recommend, and what support is available?
• Can I get a referral to pulmonary rehabilitation?
• Am I up to date on all recommended vaccinations, including RSV?
• Do I need supplemental oxygen? If so, how many hours per day?
• Can we create a written COPD action plan together?
• What exercise is safe for me, and how should I start?
• Am I at risk for depression or anxiety, and how is that being addressed?
• What should I do when traveling with COPD?
• Should I see a palliative care specialist for symptom management?
• Are there local support groups for COPD patients and caregivers?

• Write your top 3–5 questions in advance.
• Bring a current list of all medications (including inhalers, supplements, and over-the-counter drugs) with doses and times.
• Bring your inhalers to every visit so your technique can be checked.
• Bring someone with you, or ask to record the conversation.
• Know your key numbers: FEV1, GOLD grade, ABE group, eosinophil count, and oxygen saturation.
• Track your symptoms: how breathless are you on a typical day? How many times per week do you use your rescue inhaler? Have your symptoms changed?
• Report any exacerbations (worsening episodes) since your last visit, including whether you needed steroids, antibiotics, or emergency care.

• Daily symptoms: breathlessness level, cough frequency, sputum amount and color
• Rescue inhaler use: how many times per day/week
• Activity level: how far you can walk, what activities you can do
• Oxygen saturation (if you have a pulse oximeter)
• Weight changes (unintentional weight loss is a warning sign)
• Sleep quality and nighttime symptoms
• Exacerbations: dates, triggers, treatments needed, and outcomes
• Medication adherence: are you taking all your medications as prescribed?
• Mood: anxiety, depression, social isolation
• Vaccinations: keep a record and bring it to appointments

COPD is uncommon during the reproductive years, but it can occur — particularly in people with alpha-1 antitrypsin deficiency or a long smoking history. If you have COPD and are pregnant or planning a pregnancy, the guiding principle is that uncontrolled COPD poses a greater risk to you and your baby than most inhaled medications, because poorly controlled disease can lower the oxygen your baby receives.

• Keep breathing well. Most inhaled maintenance therapies — long-acting bronchodilators (LABA, LAMA) and inhaled corticosteroids (ICS) — are generally continued in pregnancy when needed to keep your breathing controlled. Do not stop your inhalers on your own; discuss any changes with your doctor.
• Stopping smoking is the single most important step. Quitting protects both your lung function and your baby’s growth and development. Ask about pregnancy-safe cessation support; counseling is first-line, and any medication use should be decided with your obstetric and pulmonary teams.
• Exacerbations are treated. A flare-up during pregnancy is still treated actively — this can include short courses of systemic corticosteroids and antibiotics when indicated — because an untreated exacerbation is more dangerous than the treatment.
• Vaccines protect you both. Influenza, COVID-19, and other recommended vaccinations are important in pregnancy and help prevent respiratory infections that can trigger exacerbations.
• Biologics and newer agents. There is limited pregnancy data for the newer COPD therapies (dupilumab, mepolizumab, ensifentrine). Decisions about continuing or pausing them should be individualized with your care team, weighing your disease severity against the available safety information.

Questions to ask your doctor: Which of my inhalers should I keep taking during pregnancy? How will we manage a flare-up safely? What cessation support is safe for me now? Should I see a high-risk obstetrics (maternal-fetal medicine) specialist?

• FEV1/FVC — Forced Expiratory Volume in 1 second / Forced Vital Capacity. FEV1 is the amount of air you can blow out in one second; FVC is the total amount you can blow out. The FEV1/FVC ratio is the cornerstone of COPD diagnosis — a post-bronchodilator ratio below 0.70 confirms airflow obstruction.
• GOLD grade (1–4) — the severity of airflow limitation based on FEV1 as a percentage of the predicted normal value. Grade 1 (mild): FEV1 ≥80%. Grade 2 (moderate): 50–79%. Grade 3 (severe): 30–49%. Grade 4 (very severe): <30%.
• ABE groups — the GOLD 2026 assessment tool that guides initial treatment based on exacerbation history and symptom burden. Group A: fewer symptoms, 0–1 moderate exacerbation/year. Group B: more symptoms, 0–1 moderate exacerbation/year. Group E (Exacerbation): ≥2 moderate or ≥1 hospitalized exacerbation/year, regardless of symptoms.
• Eosinophils — a type of white blood cell measured by a simple blood count. The blood eosinophil count (BEC) is a key biomarker in COPD that guides whether inhaled corticosteroids and biologic therapies will be effective. Counts ≥300 cells/μL strongly favor ICS and biologic eligibility; counts <100 cells/μL suggest ICS is unlikely to help.
• LAMA — Long-Acting Muscarinic Antagonist. A class of inhaled bronchodilator that relaxes airway smooth muscle by blocking acetylcholine receptors (e.g., tiotropium, umeclidinium, glycopyrrolate). Taken once or twice daily for maintenance.
• LABA — Long-Acting Beta-Agonist. A class of inhaled bronchodilator that relaxes airway smooth muscle by stimulating beta-2 receptors (e.g., salmeterol, formoterol, vilanterol, olodaterol). Taken once or twice daily for maintenance.
• ICS — Inhaled Corticosteroid. An anti-inflammatory inhaler that reduces airway inflammation. Used selectively in COPD, guided by blood eosinophil count and exacerbation history. Examples: fluticasone, budesonide.
• Triple therapy — the combination of LAMA + LABA + ICS delivered in a single inhaler device. Two products are available: Trelegy Ellipta (once daily) and Breztri Aerosphere (twice daily). Shown to reduce exacerbations by about 25% compared to dual bronchodilators alone.
• Exacerbation — a flare-up of COPD symptoms (worsening breathlessness, increased cough or sputum, change in sputum color) that is beyond normal day-to-day variation and requires a change in treatment — typically oral corticosteroids, antibiotics, or hospitalization. Each severe exacerbation can cause a permanent drop in lung function.
• Pulmonary rehabilitation — a structured, supervised program of exercise training, breathing techniques, education, nutritional counseling, and self-management support for people with chronic lung disease. The most effective non-drug treatment for COPD, yet used by fewer than 5% of eligible patients.
• AATD — Alpha-1 Antitrypsin Deficiency. A genetic condition (affecting roughly 1 in 2,500 people of European descent) in which the liver does not produce enough of a protein that protects the lungs from damage. Causes emphysema, sometimes at an unusually young age. Treatable with augmentation therapy. Every COPD patient should be tested at least once.

• University of Utah Pulmonary Division — the primary academic pulmonary center in the Intermountain West. Subspecialty expertise in COPD, emphysema, alpha-1 antitrypsin deficiency, and pulmonary hypertension. Offers comprehensive pulmonary function testing, bronchoscopic lung volume reduction (Zephyr endobronchial valves), the University of Utah Lung Transplant Program, and clinical trial access for COPD biologics and novel therapies. Houses the University of Utah Pulmonary Rehabilitation Program with supervised outpatient exercise, education, and self-management training. Phone: 801-581-2121 (University of Utah Health main line).
• Intermountain Health — COPD diagnosis and management across the Wasatch Front and beyond. Pulmonary rehabilitation programs at multiple Intermountain locations. Referral pathways to the University of Utah for complex cases, bronchoscopic procedures, and transplant evaluation. Phone: 801-442-2000.
• George E. Wahlen VA Medical Center (Salt Lake City) — comprehensive COPD care for enrolled veterans including spirometry, pulmonary rehabilitation, smoking cessation programs, oxygen therapy, and referral pathways to the University of Utah for advanced procedures. Phone: 801-582-1565.
• Utah Tobacco Quit Line — 1-800-QUIT-NOW (1-800-784-8669). Free telephone-based smoking cessation counseling and, for eligible Utah residents, free nicotine replacement therapy (patches, gum, lozenges). Available in English and Spanish. Also available online at waytoquit.org. Smoking cessation is the most important single intervention for COPD — call today.

• National Jewish Health (Denver, Colorado) — the nation's leading respiratory hospital, consistently ranked #1 in pulmonology by U.S. News & World Report. Comprehensive COPD and emphysema programs including advanced diagnostics, biologic therapy, lung volume reduction, clinical trials, and alpha-1 antitrypsin deficiency expertise. Only 6 hours from Salt Lake City. Accepts out-of-state referrals and most insurance. Phone: 1-800-222-5864. nationaljewish.org
• Mayo Clinic Pulmonary & Critical Care (Rochester, MN; Scottsdale, AZ; Jacksonville, FL) — multidisciplinary COPD evaluation including advanced phenotyping, biologic therapy, bronchoscopic and surgical lung volume reduction, lung transplant, and an active clinical trial portfolio. Phone: 1-507-284-2511 (Rochester). mayoclinic.org
• Cleveland Clinic Respiratory Institute (Cleveland, OH) — one of the largest respiratory programs in the country. Expertise in complex COPD management, lung volume reduction, transplantation, and pulmonary rehabilitation research. Phone: 1-800-223-2273. clevelandclinic.org

• George E. Wahlen VA Medical Center — Pulmonary Services (Salt Lake City) — provides comprehensive COPD care for enrolled veterans including spirometry and pulmonary function testing, inhaler management, pulmonary rehabilitation, smoking cessation programs, oxygen therapy, and referral pathways for advanced care. Veterans with service-connected respiratory conditions or occupational lung exposures should discuss COPD screening with their VA primary care provider. Phone: 801-582-1565.
• Veterans eligible for community care may also be referred to University of Utah or Intermountain for specialized procedures not available at the VA.

• University Health Network — Toronto General Hospital, Respirology Division — one of Canada's largest respiratory medicine programs. Expertise in advanced COPD management, lung transplantation, pulmonary rehabilitation, and clinical trials. Phone: 1-416-340-4800. uhn.ca
• McGill University Health Centre — Respiratory Division (Montreal) — comprehensive COPD care including advanced diagnostics, biologic therapy, pulmonary rehabilitation, and the Montreal Chest Institute. Phone: 1-514-934-1934. muhc.ca
• University of British Columbia — Centre for Heart Lung Innovation (Vancouver) — COPD research and clinical care with expertise in phenotyping, biologics, and clinical trials. Phone: 1-604-875-4111 (Vancouver General Hospital). hli.ubc.ca
• Canadian Thoracic Society (CTS) — the national respiratory medicine society. Develops Canadian COPD guidelines (CTS/CHTPE position statements) and provides physician and patient resources. Works with the Canadian Lung Association on education and advocacy. cts-sct.ca
• Lung Health Foundation (Ontario) — Canada's leading lung health charity. Provides COPD education, a Lung Health Information Line, pulmonary rehabilitation directories, smoking cessation support, and advocacy for lung health research and policy. lunghealth.ca
• Canadian patients should also consult their provincial health authority for pulmonary rehabilitation programs and respiratory specialist referrals. COPD biologics (dupilumab, mepolizumab) are available in Canada but may have different coverage and approval criteria than in the US — check with your provincial drug plan.

• Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust (London, UK) — one of Europe's largest specialist respiratory centers. Advanced COPD management including biologics, endobronchial valve therapy, lung volume reduction surgery, lung transplantation, and clinical trials. Phone: +44 20 7352 8121. rbht.nhs.uk
• Charité — Universitätsmedizin Berlin, Department of Pneumology (Germany) — leading European respiratory medicine program with expertise in COPD phenotyping, interventional pulmonology, and clinical trials. Phone: +49 30 450 553 051. charite.de
• National Hospital Organization Kinki-Chuo Chest Medical Center (Osaka, Japan) — a major Japanese respiratory referral center with COPD expertise, pulmonary rehabilitation, and clinical trial access. JRS-affiliated. Phone: +81 72-252-3021.
• Global Initiative for Chronic Obstructive Lung Disease (GOLD) — the international body that produces the COPD guidelines used by clinicians worldwide. Patient-friendly guideline summaries available. goldcopd.org

Key areas of active investigation include:

• Biologics for eosinophilic COPD — beyond dupilumab and mepolizumab, several biologics targeting different inflammatory pathways are in clinical trials. Itepekimab (anti-IL-33) and tezepelumab (anti-TSLP) target upstream "alarm" signals that trigger eosinophilic inflammation. These could offer new options for patients who do not respond adequately to current biologics or who have different inflammatory profiles.
• PDE3/4 inhibitors — ensifentrine was the first in this class; newer dual PDE3/PDE4 inhibitors (such as HRS-9821, in development by GSK/Hengrui) and fixed-dose combinations (ensifentrine + glycopyrrolate) are in the pipeline. These aim to deliver bronchodilation and anti-inflammatory effects without corticosteroids.
• Bronchoscopic interventions — beyond endobronchial valves, researchers are studying bronchoscopic thermal vapor ablation, targeted lung denervation, and biologic lung sealants for emphysema. These minimally invasive procedures aim to reduce hyperinflation and improve breathing without major surgery.
• Gene and RNA therapies for AATD — RNA interference (RNAi) therapies (fazirsiran, Phase 3) and AAV-based gene therapies (Phase 1) could eventually replace lifelong weekly infusions of alpha-1 antitrypsin protein.
• Mucolytics and airway clearance — novel mucolytic agents and devices are being studied for the chronic bronchitis phenotype, aiming to reduce mucus burden and exacerbation frequency.
• Disease modification — GOLD 2026 formally recognizes "disease activity" as a treatment target. Research is exploring whether early, aggressive treatment can modify the long-term trajectory of COPD, not just manage symptoms.

• ClinicalTrials.gov — the US National Library of Medicine registry. Search for "COPD" and filter by your location (e.g., Utah), status (recruiting), and trial phase. Each listing includes eligibility criteria, contact information, and study sites. clinicaltrials.gov
• COPD Foundation Clinical Trial Finder — a patient-friendly search tool specifically for COPD trials. copdfoundation.org
• University of Utah Clinical Trials Office — contact for information about COPD trials available at the U of U and affiliated sites.
• Ask your pulmonologist — your doctor can help determine whether you meet the eligibility criteria for specific trials and whether participation is appropriate for your disease stage and phenotype.
• What to expect: clinical trials involve informed consent, screening visits, regular monitoring, and follow-up. Participation is voluntary, and you can withdraw at any time. You may receive the investigational treatment or a placebo (inactive treatment), depending on the trial design. Your standard COPD care continues regardless.

• Where can I access pulmonary rehabilitation in my area?
• Am I up to date on all recommended vaccinations, including the new RSV vaccine?
• Are there clinical trials I should consider based on my COPD phenotype?
• Should I be referred to a specialty pulmonary center for advanced evaluation?
• What financial assistance programs can help with the cost of my medications?
• Can I be referred to a social worker or financial navigator?
• Is there a COPD support group near me or online?
• Should I have a palliative care consultation for symptom management?
• Am I a candidate for lung transplant evaluation?
• Who should I call if my symptoms suddenly worsen outside of office hours?

• Triple therapy: Both Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) and Trimbow (beclometasone/formoterol/glycopyrronium, by Chiesi) are EMA-approved. Trimbow is widely prescribed in Europe but is not available in the United States. Breztri Aerosphere is also approved in the EU.
• Dupilumab (Dupixent): The EMA approved dupilumab for COPD with an eosinophilic phenotype in July 2024 — the world’s first COPD approval for the drug, ahead of the FDA (September 2024). Available in major EU markets.
• Mepolizumab (Nucala): EMA approved mepolizumab for eosinophilic COPD in 2025, consistent with FDA timing.
• Ensifentrine (Ohtuvayre): Under EMA review. Not yet approved in the EU as of May 2026.
• Roflumilast (Daxas/Daliresp): Widely available across Europe for the chronic bronchitis phenotype with FEV₁ <50%.
• Guidelines: European Respiratory Society (ERS) guidelines are broadly concordant with GOLD but place slightly greater emphasis on phenotype-based prescribing and cost-effectiveness considerations.

• NICE guidelines (NG115, updated 2024): NICE uses its own COPD classification (Group A/B/C/D historically, now aligned with GOLD ABE) and emphasizes spirometric reversibility testing. NICE specifically recommends ICS-containing regimens for patients with features of asthma-COPD overlap or elevated eosinophils.
• Triple therapy: Trelegy Ellipta and Trimbow are NICE-recommended and available through the NHS. NICE technology appraisals have assessed cost-effectiveness favorably.
• Dupilumab & mepolizumab: NICE technology appraisals are in progress. Access through the NHS may be subject to specific criteria beyond the FDA/EMA label, including cost-effectiveness thresholds.
• Pulmonary rehabilitation: NHS England provides pulmonary rehabilitation programs at no cost to patients through community respiratory services, though waiting times vary by region.

• Japanese Respiratory Society (JRS) guidelines: JRS publishes its own COPD guidelines that are broadly aligned with GOLD but with specific emphasis on the phenotypic overlap between asthma and COPD (ACO), which is considered more prevalent in Japanese populations.
• Triple therapy: Trelegy Ellipta and Breztri Aerosphere are PMDA-approved and available in Japan.
• Dupilumab: PMDA-approved for COPD with eosinophilic phenotype (2024–2025).
• Mepolizumab: PMDA-approved for severe eosinophilic asthma; COPD indication under review.
• Ensifentrine: Not yet approved by PMDA as of May 2026. Japanese regulatory review typically follows FDA/EMA by 12–24 months.

• Canadian Thoracic Society (CTS) guidelines: CTS guidelines are aligned with GOLD but incorporate Canadian-specific access and formulary considerations. Provincial drug plans vary — coverage for newer therapies (biologics, ensifentrine) may differ by province.
• Triple therapy: Trelegy Ellipta and Breztri Aerosphere are Health Canada-approved and available nationally, though provincial formulary listing may affect coverage.
• Dupilumab: Health Canada-approved for COPD with eosinophilic phenotype. Provincial reimbursement criteria may be stricter than the approved indication.
• Mepolizumab: Health Canada-approved for eosinophilic COPD. Coverage varies by province.
• Alpha-1 antitrypsin augmentation: Available in Canada through manufacturers and provincial programs. Canadian Blood Services does not currently fund augmentation therapy.

• Therapeutic Goods Administration (TGA): TGA approvals for COPD therapies generally follow FDA/EMA timelines. Triple therapy (Trelegy Ellipta, Breztri Aerosphere) is TGA-approved.
• Pharmaceutical Benefits Scheme (PBS): PBS listing determines affordability in Australia. Triple therapy is PBS-listed for COPD. Biologic therapies (dupilumab, mepolizumab) for COPD are under Pharmaceutical Benefits Advisory Committee (PBAC) review — PBS listing may require additional criteria beyond TGA approval.
• COPD-X guidelines: The Lung Foundation Australia and Thoracic Society of Australia and New Zealand (TSANZ) publish the COPD-X plan, a locally adapted evidence-based guideline incorporating Australian prescribing and access frameworks.